Ironwood Pharmaceuticals is a gastrointestinal (GI) healthcare company focused on developing the treatment of GI diseases. Co. is focused on the development and commercialization of GI product opportunities. LINZESS® (linaclotide), Co.'s commercial product, is a product approved by the U.S. Food and Drug Administration in a class of GI medicines called guanylate cyclase type C agonists and is indicated for adult suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation. Co. is also developing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, including interstitial cystitis / bladder pain syndrome and endometriosis. The IRWD YTD return is shown above.
The YTD Return on the IRWD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether IRWD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the IRWD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|